Designing assistive technology for getting more independence for blind people when performing everyday tasks: an auditory-based tool as a case study

Everyday activities and tasks should in theory be easily carried by everyone, including the blind. Information and Communication Technology (ICT) has been widely used for supporting solutions. However, the solutions can be problematic for the visually impaired since familiarity with digital devices is often required. Or, indeed the procedure can be perceived as fiddly or impractical particularly for repetitive tasks due to the number/type of steps required to complete the task. This paper introduces a simple audio-based tool aimed at supporting visually-impaired people in the seemingly simple activity of checking whether the light in a room is on or off. It is an example of potential low tech devices that can be designed without the need for specific skills or knowledge by the user, and that functions in a practical way. In this context, we discuss the main issues and considerations for totally blind users in identifying whether a light is switched on. The proposed prototype is based on a simple circuit and a form of auditory feedback which informs the user whether they are switching on or off the light. Two prototypes have been designed and built for two different kinds of installation. For the subsequent second prototype, three different versions are proposed to provide a blind person with further support in easily identifying the light status at home. The new design includes enhanced auditory feedback and modifications to the dimensions. The evaluation conducted by involving various groups of end-users revealed the usefulness of the proposed tool. In addition, a survey conducted with 100 visually-impaired people reported the limitations and difficulties encountered by the blind in using existing devices. Moreover, the study revealed the interest from 94% of the participants for a potential (new) basic tool integrable with the existing lighting system. This study gives a contribution in the ambient intelligence field by (1) showing how an auditory-based tool can be used to support totally blind people to check the lights in an autonomous and relatively simple way; (2) proposing an idea that can be exploited in other application cases that use light feedback; and (3) proposing seven potential recommendations for designing assistive technology tools and common everyday devices, based on information gathered from the online survey

A 1 mm Scintillating Fibre Tracker Readout by a Multi-anode Photomultiplier

This note describes a prototype particle tracking detector constructed with 1 mm plastic scintillating fibres with a 64 channel Hamamatsu H8500 flat-panel multi-anode photomultiplier readout. Cosmic ray tracks from an array of 11 gas-filled drift tubes were matched to signals in the scintillating fibres in order to measure the resolution and efficiency of tracks reconstructed in the fibre-based tracker. A GEANT4 detector simulation was also developed to compare cosmic ray data with MC results and is discussed in the note. Using the parameters measured in this experimental setup, modified fibre tracker designs are suggested to improve resolution and efficiency in future prototypes to meet modern detector specifications.Comment: Laboratori Nazionali Di Frascati SIDS-Pubblicazioni LNF - 10 / 21(P) October 26, 201

Biofortification of Lettuce and Basil Seedlings to Produce Selenium Enriched Leafy Vegetables

Selenium (Se) biofortification of plants has been recognized as a good strategy to improve the nutritive value of vegetables and increase Se daily intake in humans. Identifying the most appropriate method to enrich plants is a key issue in the biofortification process. We tested a biofortification technique that produces Se enriched seedlings for transplant, yet barely modifies conventional cultivation techniques. Lettuce (Lactuca sativa L.) and sweet basil (Ocimum basilicum L.) were exposed to selenium by adding 0, 1 and 3 mg L−1 (lettuce) and 0, 2 and 3 mg L−1 (basil) of Se, as sodium selenate, to the growing substrate immediately after sowing. When seedlings reached an appropriate size, they were transplanted into the open field, and plants were grown until maturity. Lettuce and basil seedlings accumulated selenium without any reduction in leaf biomass at maturity. The highest dose of Se induced a higher antioxidant capacity and flavonoid content in both species at both sampling times. At maturity, biofortified plants still showed a higher leaf Se content compared to the control, and would be able to provide from 10% to 17% (lettuce) and from 9% to 12% (basil) of the adequate intake (AI) of Se

Poor outcome for patients with gastric cancer and lung metastases treated with ramucirumab and paclitaxel

The aim of this report is to investigate the activity of ramucirumab in combination with paclitaxel in patients with metastatic gastric cancer (GC) and lung metastases. We retrospectively reviewed clinical data from patients with GC treated in second line with ramucirumab and paclitaxel according to the presence or not of lung metastases. Thirty-one patients were eligible. Five (16.1%) patients had lung metastases. The median progression-free survival was 156 days in patients without lung metastases compared with 54 days in patients with lung metastases. The median survival also showed a trend in favour of patients without lung metastases. Despite the small number of patients and the retrospective nature of the data, our analysis showed relatively poor efficacy of ramucirumab plus paclitaxel as a second-line treatment in patients with lung metastases from GC. Further studies are required to evaluate novel treatments in this subset of patients

Bone Targeting Agents in Patients with Prostate Cancer: General Toxicities and Osteonecrosis of the Jaw

Introduction: Bone metastases are the most frequent site of secondary localization of prostate cancer (PCa) and are present in about 90% of cases of advanced disease. Consequently, an ade-quate management of bone involvement is of pivotal importance in the therapeutic approach and skeletal-related events (SREs) need to be closely monitored and promptly assessed and treated. Bone targeting agents (BTAs), consisting in bisphosphonates and denosumab, are an essential part of the treatment of metastatic prostate cancer that accompanies systemic treatments throughout the most part of the history of the disease. Activity and safety of bone targeting agents: These treatments are correlated to better outcomes in terms of reduction of SREs and, in metastatic castration resistant setting, of increased overall survival (OS), but several important adverse events have to be managed and prevented. Of these, osteonecrosis of the jaw (ONJ) is extremely invalidating and should be managed with a special attention. Discussion: The role of BTAs in prostate cancer is pivotal throughout many stages of the disease, but several toxicities should be quickly recognized and treated. We aim at recollecting evidence on clinical benefit of BTAs, common and specific toxicities, and explore the pathophysiology and clinical aspects of osteonecrosis of the jaw. We present a review of the literature to report the role of the different types of bone targeting agents in the management of prostate cancer with bone metastases with a particular focus on common toxicities and ONJ to rec-ollect current evidences on the activity of these compounds and the correct management of their adverse events

Prognostic Factors of Survival for High-Grade Neuroendocrine Neoplasia of the Bladder: A SEER Database Analysis

Background: High-grade neuroendocrine carcinoma (NEC) is a rare and aggressive variant of bladder cancer. Considering its rarity, its therapeutic management is challenging and not standardized. Methods: We analyzed data extracted from the Surveillance, Epidemiology, and End Results (SEER) registry to evaluate prognostic factors for high-grade NEC of the bladder. Results: We extracted data on 1134 patients: 77.6% were small cell NEC, 14.6% were NEC, 5.5% were mixed neuro-endocrine non-neuroendocrine neoplasia, and 2.3% were large cell NEC. The stage at diagnosis was localized for 45% of patients, lymph nodal disease (N+M0) for 9.2% of patients, and metastatic disease for 26.1% of patients. The median overall survival (OS) was 12 months. Multivariate analysis detected that factors associated with worse OS were age being >72 years old (HR 1.94), lymph nodal involvement (HR 2.01), metastatic disease (HR 2.04), and the size of the primary tumor being >44.5 mm (HR 1.80). In the N0M0 populations, the size of the primary tumor being <44.5 mm, age being <72 years old, and major surgery were independently associated with a lower risk of death. In the N+M0 group, the size of the primary lesion was the only factor to retain an association with OS. Conclusions: Our SEER database analysis evidenced prognostic factors for high-grade NEC of the bladder that are of pivotal relevance to guide treatment and the decision-making process

International Conference on Knowledge Management

This workshop is presented by members of a University of North Texas research team. First, the team will overview their experience as members of the research team and share experience in areas such as trust formation, team roles, productivity, work-life balance, faculty-students interaction, peer and faculty mentorship, dissertation preparation, and job seeking. Second, the workshop will discuss and brainstorm how this format can be implemented for organizations both with faculty-student teams and with peer-directed teams. Finally, successes and challenges are openly discussed with audience

Association between ramucirumab-related hypertension and response to treatment in patients with metastatic gastric cancer

PURPOSE: Hypertension (HTN) is frequently associated with the use of angiogenesis inhibitors targeting the vascular endothelial growth factor pathway, such as ramucirumab. The aim of this study was to retrospectively evaluate if occurrence of HTN is correlated with response to second line treatment with ramucirumab+paclitaxel for metastatic gastric cancer. METHODS: Treatment consisted of ramucirumab 8 mg/kg intravenously (iv) on days 1 and 15, plus paclitaxel 80 mg/m2 iv on days 1, 8, and 15 of a 28-day cycle. Patients received study treatment until disease progression, unacceptable toxicity, or withdrawal of consent. RESULTS: Thirty-four patients were retrospectively evaluated. Among these, 6 (17.6%) developed grade 3 ramucirumab-induced HTN. These patients had a better outcome than those with lesser grades events, with a progression-free survival (PFS) of 7.8 months (95% CI 4.4-not reached) versus 4.2 months (95% CI 3.1-5.2) (p=0.001). overall survival (OS) was 11.9 months (95% CI 9.3-not reached) in the grade 3 HTN group, versus 7.2 months (95% CI 5.9-10.1). CONCLUSIONS: Despite the small number of patients and the retrospective nature of the data, our analysis showed that occurrence of ramucirumab-related HTN, in particular G3 HTN, predicts response to treatment with ramucirumab+paclitaxel in patients with metastatic gastric cancer

Adjuvant PD-1 and PD-L1 Inhibitors and Relapse-Free Survival in Cancer Patients: The MOUSEION-04 Study

Background: Adjuvant treatment has always been a cornerstone in the therapeutic approach of many cancers, considering its role in reducing the risk of relapse and, in some cases, increasing overall survival. Adjuvant immune checkpoint inhibitors have been tested in different malignancies. Methods: We performed a meta-analysis aimed to explore the impact of adjuvant PD-1 and PD-L1 inhibitors on relapse-free survival (RFS) in cancer patients enrolled in randomized controlled clinical trials. We retrieved all phase III trials published from 15 June 2008 to 15 May 2022, evaluating PD-1/PD-L1 inhibitors monotherapy as an adjuvant treatment by searching on EMBASE, Cochrane Library, and PubMed/ Medline, and international oncological meetings’ abstracts. The outcome of interest was RFS. We also performed subgroup analyses focused on age and gender. Results: Overall, 8 studies, involving more than 6000 patients, were included in the analysis. The pooled results highlighted that the use of adjuvant PD-1/PD-L1 inhibitors may reduce the risk of relapse compared to control treatments (hazard ratio, 0.72; 95% confidence intervals, 0.67–0.78). In addition, the subgroup analyses observed that this benefit was consistent in different patient populations, including male, female, younger, and older patients. Conclusions: Adjuvant anti-PD-1/PD-L1 treatment is associated with an increased RFS in the overall population and in subgroups divided according to age and gender